Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

Pemetrexed 22Carboplatin 22Cisplatin 19Paclitaxel 9Gemcitabine 9pembrolizumab 8osimertinib 7Nivolumab 6Crizotinib 6durvalumab 5atezolizumab 5amivantamab 4Ipilimumab 4Docetaxel 4Afatinib 4tremelimumab 3lazertinib 3Vinorelbine 3Gefitinib 3Etoposide 3Albumin-Bound Paclitaxel 3trametinib 2selpercatinib 2lorlatinib 2larotrectinib 2dabrafenib 2cemiplimab 2binimetinib 2alectinib 2PM 01183 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × ceritinib × Thoracic × Clear all
NCT01828099 2025-01-16

LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

Novartis

Phase 3 Completed
376 enrolled 34 charts 1 FDA
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡